Vall d'Hebron Institute of Oncology (VHIO)
Noelia Alcazar Perez, PhD, currently serves as a Field Application Specialist at Bonsai Lab since April 2024. Previously, Noelia held the position of Lab Manager at the Vall d´Hebron Institute of Oncology (VHIO) from June 2020 to April 2024, where involvement was with the Tumor Immunology & Immunotherapy Group under the leadership of Dra. Noelia's early research experience includes a significant tenure as a PhD Researcher at IRB Barcelona and the Spanish National Cancer Research Centre (CNIO) from May 2017 to June 2020 and February 2013 to May 2017, respectively, both under the guidance of Dr. Manuel Serrano. Noelia completed a PhD in Molecular Bioscience, graduating Cum Laude from Universidad Autónoma de Madrid, where also a Master’s degree in Molecular Bioscience was obtained. Academic foundations were laid at Universidad Francisco de Vitoria, culminating in an Expert in Biotechnological Research Methodology.
This person is not in any teams
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.